SG11201808915YA - Chagas antigens and antibodies and compositions, methods and uses thereof - Google Patents
Chagas antigens and antibodies and compositions, methods and uses thereofInfo
- Publication number
- SG11201808915YA SG11201808915YA SG11201808915YA SG11201808915YA SG11201808915YA SG 11201808915Y A SG11201808915Y A SG 11201808915YA SG 11201808915Y A SG11201808915Y A SG 11201808915YA SG 11201808915Y A SG11201808915Y A SG 11201808915YA SG 11201808915Y A SG11201808915Y A SG 11201808915YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- london
- rule
- ec4a
- limited
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/005—Trypanosoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) REVISED VERSION --, (19) World Intellectual Property Organization 1111111011111111101 111111111101011101110101H111111111111111111111111110111111111111 International Bureau (10) International Publication Number l i (43) International Publication Date ...../ WO 2017/178660 A9 19 October 2017 (19.10.2017) WIPO I PCT (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, A61K 39/005 (2006.01) C07K 14/44 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, PCT/EP2017/059189 HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (22) International Filing Date: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, 18 April 2017 (18.04.2017) PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (25) Filing Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 62/322,770 14 April 2016 (14.04.2016) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (71) Applicant: PEPTCELL LIMITED [GB/GB]; 100 Fetter UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Lane, London Greater London EC4A 1BN (GB). EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (72) Inventors: PLEGUEZUELOS MATEO, Olga; c/o PepT- MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, cell Limited, 100 Fetter Lane, London Greater London TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, EC4A 1BN (GB). CAPARROS-WANDERLEY, Wilson, KM, ML, MR, NE, SN, TD, TG). Romero; c/o PepTcell Limited, 100 Fetter Lane, London Greater London EC4A 1BN (GB). STOLOFF, Grego- Declarations under Rule 4.17: ry, Alan; c/o PepTcell Limited, 100 Fetter Lane, London — as to applicant's entitlement to apply for and be granted a Greater London EC4A 1BN (GB). patent (Rule 4.1700) (74) Agent: SCHLICH; 9 St. Catherine's Road, Littlehampton West Sussex BN17 5HS (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (54) Title: CHAGAS ANTIGENS AND ANTIBODIES 100 80 60 Tv 3 40 • A AND COMPOSITIONS, METHODS AND USES THEREOF -a- A+C (control) -0- B D 20 01 0 5 10 15 20 25 30 35 40 45 50 0 Day (pi) IN pc Fig. 12 ,-, N (57) : The present specification discloses Trypanosoma antigens, immunogenic compositions and medicaments comprising 1-1 C such Trypanosoma antigens, methods and uses for such Trypanosoma antigensand immunogenic compositions for treating a Trypano so- ei ma-based disease. C [Continued on next page] WO 2017/178660 A9 IMEDIMOM0101011MOIDEMOMOINIDER011001101MEMHO# Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) — with sequence listing part of description (Rule 5.2(a)) (88) Date of publication of the revised international search report: 07 December 2017 (07.12.2017) (15) Information about Correction: see Notice of 07 December 2017 (07.12.2017)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662322770P | 2016-04-14 | 2016-04-14 | |
PCT/EP2017/059189 WO2017178660A1 (en) | 2016-04-14 | 2017-04-18 | Chagas antigens and antibodies and compositions, methods and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201808915YA true SG11201808915YA (en) | 2018-11-29 |
Family
ID=58671580
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201808915YA SG11201808915YA (en) | 2016-04-14 | 2017-04-18 | Chagas antigens and antibodies and compositions, methods and uses thereof |
Country Status (18)
Country | Link |
---|---|
US (2) | US10973897B2 (en) |
EP (1) | EP3442569A1 (en) |
JP (1) | JP2019513797A (en) |
KR (1) | KR20190039022A (en) |
CN (2) | CN109310747B (en) |
AU (1) | AU2017248680A1 (en) |
BR (1) | BR112018071108A2 (en) |
CA (1) | CA3020856A1 (en) |
CL (2) | CL2018002932A1 (en) |
CO (1) | CO2018012295A2 (en) |
CU (1) | CU20180127A7 (en) |
EC (1) | ECSP18079073A (en) |
MX (1) | MX2018012504A (en) |
NI (1) | NI201800105A (en) |
PE (1) | PE20190104A1 (en) |
RU (1) | RU2018139865A (en) |
SG (1) | SG11201808915YA (en) |
WO (1) | WO2017178660A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220088161A1 (en) * | 2019-01-07 | 2022-03-24 | Genome Research Limited | Novel trypanosomal vaccine |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2731370A1 (en) * | 1977-07-12 | 1979-01-25 | Behringwerke Ag | CHAGA'S VACCINE AND METHOD OF MANUFACTURING IT |
ES2169995B1 (en) | 2000-04-17 | 2003-12-01 | Leti Lab | LIP2A PROTEIN BASED COMPOSITION AND ITS USE IN THE PREPARATION OF A MEDICINAL PRODUCT TO PROVIDE AN IMMUNE RESPONSE AGAINST AN ANTIGEN. |
US20040057958A1 (en) | 2002-05-17 | 2004-03-25 | Waggoner David W. | Immunogenicity-enhancing carriers and compositions thereof and methods of using the same |
SA110310855B1 (en) * | 2009-11-13 | 2014-09-16 | Laboratories Leti S L Unipersonal | The Use of an l3 and/or l5 Source as a Vaccine or as a Diagnostic for a Parasitic Disease |
US9804158B2 (en) | 2013-07-02 | 2017-10-31 | Institut De Recherche Pour Le Développement | Peptides and methods for the detection of Leishmaniasis |
US9566320B2 (en) | 2013-09-24 | 2017-02-14 | The Board Of Regents Of The University Of Texas System | Mucin-associated surface protein as vaccine against Chagas disease |
-
2017
- 2017-04-14 US US15/487,935 patent/US10973897B2/en active Active
- 2017-04-18 CA CA3020856A patent/CA3020856A1/en active Pending
- 2017-04-18 CN CN201780037260.8A patent/CN109310747B/en active Active
- 2017-04-18 RU RU2018139865A patent/RU2018139865A/en not_active Application Discontinuation
- 2017-04-18 MX MX2018012504A patent/MX2018012504A/en unknown
- 2017-04-18 CU CU2018000127A patent/CU20180127A7/en unknown
- 2017-04-18 WO PCT/EP2017/059189 patent/WO2017178660A1/en active Application Filing
- 2017-04-18 KR KR1020187032828A patent/KR20190039022A/en unknown
- 2017-04-18 EP EP17721544.9A patent/EP3442569A1/en active Pending
- 2017-04-18 CN CN202211370674.1A patent/CN116059330A/en active Pending
- 2017-04-18 BR BR112018071108-0A patent/BR112018071108A2/en not_active Application Discontinuation
- 2017-04-18 AU AU2017248680A patent/AU2017248680A1/en not_active Abandoned
- 2017-04-18 JP JP2018554466A patent/JP2019513797A/en active Pending
- 2017-04-18 SG SG11201808915YA patent/SG11201808915YA/en unknown
- 2017-04-18 PE PE2018001985A patent/PE20190104A1/en not_active Application Discontinuation
-
2018
- 2018-10-12 CL CL2018002932A patent/CL2018002932A1/en unknown
- 2018-10-12 NI NI201800105A patent/NI201800105A/en unknown
- 2018-10-19 EC ECSENADI201879073A patent/ECSP18079073A/en unknown
- 2018-11-14 CO CONC2018/0012295A patent/CO2018012295A2/en unknown
-
2021
- 2021-04-03 US US17/221,788 patent/US20210220453A1/en active Pending
- 2021-06-02 CL CL2021001441A patent/CL2021001441A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA3020856A1 (en) | 2017-10-19 |
BR112018071108A2 (en) | 2019-02-26 |
CN109310747A (en) | 2019-02-05 |
CN116059330A (en) | 2023-05-05 |
ECSP18079073A (en) | 2019-02-28 |
CO2018012295A2 (en) | 2019-04-30 |
MX2018012504A (en) | 2019-08-29 |
CL2018002932A1 (en) | 2019-02-01 |
US20170296637A1 (en) | 2017-10-19 |
US20210220453A1 (en) | 2021-07-22 |
NI201800105A (en) | 2019-02-18 |
CN109310747B (en) | 2022-11-22 |
RU2018139865A (en) | 2020-05-14 |
WO2017178660A1 (en) | 2017-10-19 |
PE20190104A1 (en) | 2019-01-15 |
JP2019513797A (en) | 2019-05-30 |
CL2021001441A1 (en) | 2021-11-19 |
KR20190039022A (en) | 2019-04-10 |
US10973897B2 (en) | 2021-04-13 |
CU20180127A7 (en) | 2019-08-06 |
WO2017178660A9 (en) | 2017-12-07 |
AU2017248680A1 (en) | 2018-11-22 |
EP3442569A1 (en) | 2019-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201903514VA (en) | Novel cd47 monoclonal antibodies and uses thereof | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
SG11201805320XA (en) | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration | |
SG11201906200WA (en) | Nucleic acid-polypeptide compositions and methods of inducing exon skipping | |
SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
SG11201906192SA (en) | Methods of treating cancer with anti-pd-1 antibodies | |
SG11201810023QA (en) | Anti-tim-3 antibodies and methods of use thereof | |
SG11201901020RA (en) | Anti-siglec-7 antibodies for the treatment of cancer | |
SG11201909949XA (en) | Targeted immunotolerance | |
SG11201809700YA (en) | Gdf15 fusion proteins and uses thereof | |
SG11201810465RA (en) | Compositions and methods related to engineered fc constructs | |
SG11201804814YA (en) | Materials and methods for delivering nucleic acids to cochlear and vestibular cells | |
SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
SG11201804375WA (en) | Compositions and methods for internalizing enzymes | |
SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
SG11201806342SA (en) | Glucagon and glp-1 co-agonists for the treatment of obesity | |
SG11201810525XA (en) | Anti-gitr antibodies and uses thereof |